Back to results
US 12,728,122 B2Granted
Treatment of urothelial and kidney cancers by use of endothelin B receptor antagonists
AssigneeENB Therapeutics, Inc.
InventorSumayah Jamal
Life of this patent
Estimating the term…
Abstract
Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers such as urothelial, bladder, and kidney cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
Claims14
A method of treating urothelial cancer in a subject in need thereof, comprising administering to said subject:
- (a) an endothelin B receptor (ETBR) antagonist having the structure:
- and
- (b) an anti-PD1 antibody, wherein said administering is effective to treat said urothelial cancer in said subject.
Dependencies are inferred from the claim text.